

1     **Generation of false positive SARS-CoV-2 antigen results with testing conditions outside manufacturer**  
2                     **recommendations: A scientific approach to pandemic misinformation**

3     Glenn Patriquin<sup>1,2</sup>, Ross J. Davidson<sup>1-4</sup>, Todd F. Hatchette<sup>1-4</sup>, Breanne M. Head<sup>5</sup>, Edgard Mejia<sup>5</sup>, Michael G.  
4     Becker<sup>5</sup>, Adrienne Meyers<sup>5</sup>, Paul Sandstrom<sup>5</sup>, Jacob Hatchette<sup>6</sup>, Ava Block<sup>6</sup>, Nicole Smith<sup>6</sup>, John Ross<sup>6</sup>,  
5     Jason J. LeBlanc<sup>1-4\*</sup>

6     <sup>1</sup>Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health (NSH),  
7     Halifax, Nova Scotia, Canada.

8     <sup>2</sup>Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.

9     <sup>3</sup>Department of Medicine (Infectious Diseases), Dalhousie University, Halifax, Nova Scotia, Canada.

10    <sup>4</sup>Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.

11    <sup>5</sup>National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, Manitoba,  
12    Canada.

13    <sup>6</sup>Praxes Medical Group, Halifax, Nova Scotia, Canada.

14    **Key Words:** COVID-19, SARS-CoV-2, antigen, false positive, Panbio

15    **Abstract word count:** 250

16    **Body word count:** 2989

17    **\*Corresponding author:**         Jason J. LeBlanc, PhD, FCCM, D(ABMM)  
18   Division of Microbiology, Department of Pathology and Laboratory  
19   Medicine, Nova Scotia Health (NSH),  
20   Room 404B, MacKenzie Building  
21   5788 University Avenue, Halifax, Nova Scotia, B3H 1V8  
22   Tel.: +1 902 473 7698; Fax: +1 902 473 7971  
23   Email: [jason.leblanc@nshealth.ca](mailto:jason.leblanc@nshealth.ca)

24 **Abstract**

25 **Objectives.** Antigen-based rapid diagnostics tests (Ag-RDTs) are useful tools for SARS-CoV-2 detection.  
26 However, misleading demonstrations of the Abbott Panbio COVID-19 Ag-RDT on social media claimed  
27 that SARS-CoV-2 antigen could be detected in municipal water and food products. To offer a scientific  
28 rebuttal to pandemic misinformation and disinformation, this study explored the impact of using the  
29 Panbio SARS-CoV-2 assay with conditions falling outside of manufacturer recommendations.

30 **Methods.** Using Panbio, various water and food products, laboratory buffers, and SARS-CoV-2-negative  
31 clinical specimens were tested, with and without manufacturer buffer. Additional experiments were  
32 conducted to assess the role of each Panbio buffer component (tricine, NaCl, pH, and tween-20), as well  
33 as the impact of temperatures (4°C, 20°C, and 45°C) and humidity (90%) on assay performance.

34 **Results.** Direct sample testing (without the kit buffer), resulted in false positive signals resembling those  
35 obtained with SARS-CoV-2-positive controls tested under proper conditions. The likely explanation of  
36 these artifacts is non-specific interactions between the SARS-CoV-2-specific conjugated and capture  
37 antibodies, as proteinase K treatment abrogated this phenomenon, and thermal shift assays showed pH-  
38 induced conformational changes under conditions promoting artifact formation. Omitting, altering, and  
39 reverse engineering the kit buffer all supported the importance of maintaining buffering capacity, ionic  
40 strength, and pH for accurate kit function. Interestingly, the Panbio assay could tolerate some extremes  
41 of temperature and humidity outside of manufacturer claims.

42 **Conclusions.** Our data support strict adherence to manufacturer instructions to avoid false positive  
43 SARS-CoV-2 Ag-RDT reactions, otherwise resulting in anxiety, overuse of public health resources, and  
44 dissemination of misinformation.

45

## 46 **Introduction**

47 High demand for diagnostic testing during the COVID-19 pandemic led to the development of various  
48 technologies for SARS-CoV-2 detection.[1] Nucleic acid amplification tests (NAATs), like real-time RT-  
49 PCR, are considered the reference methods [2-4], but antigen-based rapid diagnostic tests (Ag-RDTs)  
50 have been widely used due to their ease-of use, rapid results, and ability to be performed outside of a  
51 laboratory setting.[1] Many Ag-RDTs have been licensed as point-of-care (POC) devices for SARS-CoV-2  
52 detection [5,6], but their performance can vary between methods, testing frequency, and settings in  
53 which they are used.[7-13] Ag-RDTs are well recognized to be less sensitive and specific than commercial  
54 NAATs, and false positive results from Ag-RDTs are known to occur, particularly in settings of low disease  
55 prevalence.[14,15]

56 Recently, misleading demonstrations of a SARS-CoV-2 Ag-RDT (i.e. Panbio) on social media platforms  
57 have claimed that SARS-CoV-2 antigen can readily be detected in municipal water and commercial food  
58 and beverages; however, direct testing of samples onto Ag-RDTs devices is not recommended by the  
59 manufacturer. With misinformation and disinformation often perpetuated on social media,  
60 unsubstantiated claims can undermine confidence in SARS-CoV-2 diagnostic testing and erode trust in  
61 public health efforts. As such, it is important to use science-based approaches to demonstrate that non-  
62 specific reactivity can occur when testing is performed under inappropriate conditions, and that SARS-  
63 CoV-2 is not truly present in food or potable water samples. This study evaluated conditions that fell  
64 outside of those recommended by the manufacturer, which had the potential to generate aberrant Ag-  
65 RDT reactions, including unregulated buffering capacity or ionic strength, and extremes of temperature,  
66 humidity, and pH.

## 67 **Materials and methods**

68 *Samples types*

69 Ag-RDT samples included food products (Table S1), water, laboratory buffers, specimen transport media,  
70 and 30 each of four different clinical specimens types: 1) nasopharyngeal (NP) swabs in universal  
71 transport media (UTM); 2) oropharyngeal and bilateral nares (OP/N) swabs in phosphate buffered saline  
72 (PBS) [16,17]; 3) bronchoalveolar lavages (BAL); and 4) saline gargles (Table 1).[18,19]

### 73 *Antigen and molecular testing*

74 SARS-CoV-2 nucleocapsid antigen detection was performed using the Abbott Panbio COVID-19 Rapid  
75 Antigen Test and the BD Veritor System for Rapid Detection of SARS-CoV-2. Each kit's nasal swabs were  
76 dipped into the test samples, placed in the appropriate kit buffers, and 3 or 5 drops were used to  
77 inoculate the sample wells of the Veritor and Panbio cassettes, respectively, as per the manufacturer  
78 recommendations. Each sample was also tested without manufacturer buffer (i.e. direct sample testing),  
79 mirroring the procedure and volume recommended for buffer. Results were visualized by the unaided  
80 eye after 15 minutes, and Veritor readouts also included automated detection using a BD Veritor Plus  
81 instrument. Real-time RT-PCR testing was performed for all specimens except food products using the  
82 Roche Diagnostics cobas SARS-CoV-2 Test on the cobas 6800 instrument.

### 83 *Assessing Panbio buffer components*

84 The exact composition of Panbio buffer is proprietary, yet according to the product insert, it consists of  
85 tricine, sodium chloride (NaCl), tween-20, proclin 300, and sodium azide (<0.1%). To assess the role of  
86 these components, the buffer was reverse engineered. PCR-grade water (Invitrogen) was chosen as a  
87 representative matrix to generate false positive Panbio results (Table 1). Solutions of tricine (1 mM to  
88 1M), from pH 3 to 12 were prepared (Figure 1), with or without 1% tween-20. The contribution of ionic  
89 strength was assessed using NaCl (1 mM to 1M) in 100 mM tricine solutions pH 3 to 12 (Figure 2).

90

91 *Effect of temperature and humidity on Ag-RDT performance*

92 Dilutions of gamma-irradiated SARS-CoV-2 were assessed at pre-treatment and operational  
93 temperatures within (20°C), below (4°C), or above [45°C, 90% relative humidity (RH)] the recommended  
94 test conditions (Document S1 and Table S2). Additional experiments evaluated freezing Panbio test  
95 components at -20°C, or long-term incubation (16h) at high humidity and temperature (Document S1).  
96 To assess the limit of tolerance to water-induced artifacts, Panbio buffer was serially diluted and tested  
97 at 4°C, 20°C, and 37°C (Figure 3).

98 *Investigation of environmental conditions on PanBio performance*

99 According to manufacturer specifications, PanBio kits should be stored between 2 to 30 °C, and all kit  
100 components brought to room temperature (15 to 30 °C) for 30 minutes prior to use. To assess the  
101 impact of storage temperature, sealed PanBio test devices were incubated for one hour at 4°C, 20°C or  
102 45°C (with 90% relative humidity using a Binder Constant Climate Chamber model KBF 115). Test devices  
103 were removed from their packaging, and incubations were repeated under the same conditions. Testing  
104 was performed using 20 µL of gamma-irradiated SARS-CoV-2 into 280 µL of PanBio buffer. Viral stocks  
105 [at  $1.2 \times 10^6$  plaque forming units (PFU)/mL] were diluted in PBS (pH = 7.4) to concentrations spanning  
106  $1.2 \times 10^5$  to  $1.1 \times 10^3$  PFU/mL (Supplemental Table S2). PanBio buffer and PBS were used as negative  
107 controls. Freeze-thaw effects were investigated by incubation of test components at -20°C for 16 hours  
108 before thawing and testing. Long-term exposure to high temperature and humidity was investigated by  
109 removing test components from packaging and subjecting them to 16 hours at 45°C (with 90% relative  
110 humidity).

111 *Investigations into possible causes of false positive results*

112 Using "conjugate pad transplantation" (Figure S1), the proprietary gold conjugated-antibodies of the  
113 Panbio device (i.e. the SARS-CoV-specific human IgG and the chicken IgY used for the control) were  
114 accessed from disassembled Panbio cassettes. Each conjugate pad was resuspended with 100  $\mu$ l of  
115 Panbio buffer, PCR-grade water, or tricine solutions, and the suspensions were subjected to various  
116 treatments. Proteinase K (PK) (Qiagen GmbH., Hilden, Germany) was used at 100  $\mu$ g/reaction for one  
117 hour at 56°C, followed by enzyme inactivation at 70°C for 10 minutes. Untreated and heat treatment  
118 controls were included as controls (Figure S2). The remaining conjugate-free pads are washed three  
119 times with 1 ml of water or buffer, dried using a Whatman #1 filter, and re-introduced into the Panbio  
120 cassettes. For testing, 25  $\mu$ l of each water- or buffer-derived conjugated-antibody suspension was added  
121 onto the conjugate pads of reassembled cassettes, followed by addition of 5 drops into the sample well  
122 of either positive or negative controls processed in water or the kit buffer.

123 In a second set of experiments (Figure S1, dashed lines), the control chicken IgG was removed from the  
124 SARS-CoV-2-specific IgG by pre-treatment of the conjugate suspensions with a fragment of the  
125 nitrocellulose membrane from the Panbio test device containing the immobilized mouse monoclonal  
126 anti-chicken IgY. Fragments were excised at approximately 3 mm on each side of the control line  
127 indicated on the Panbio cassette. For each 100  $\mu$ l of conjugate suspension, one fragment was added,  
128 followed by a 15 min incubation at room temperature. Then, SARS-CoV-2-specific conjugated antibody  
129 were removed and subjected to thermal shift assays [20-22] to explore possible pH-induced  
130 conformational changes (Figure S3).

### 131 *Conjugated SARS-CoV-2 IgG thermal shift assays*

132 Differential scanning fluorometry (DSF), also known as thermal shift assays, relies on monitoring  
133 temperature-dependent unfolding of a protein, in presence of a fluorescent dye that is quenched in  
134 water but fluoresces when bound to hydrophobic residues.[20-22] As a native protein is unfolded with

135 heat, different hydrophobic residues are exposed, and the melting temperature ( $T_m$ ) can be calculated  
136 for various test conditions. In this study, 25  $\mu$ l reaction containing 10 $\times$  SYPRO Orange (Invitrogen,  
137 Eugene, Oregon, USA) was added to the gold-conjugated human IgG specific to SARS-CoV-2  
138 resuspended in Panbio buffer or 100 mM of tricine at pH values spanning 3 to 12, with or without 1%  
139 tween-20. Melting curve analysis was performed by increasing the temperature from 25°C to 99.9°C at a  
140 ramp rate of 1% with continuous fluorescence at 610 nm using an Applied Biosystems 7500 Fast  
141 instrument.  $T_m$  values were calculated by manufacturer software (Figure S3).

## 142 **Results**

### 143 *False positives in food, water, buffers, media, and clinical specimens*

144 With the exception of soft drinks and some milk products which produced negative or weak false  
145 positive reactions, most of the food products that were tested directly onto the Panbio cassette  
146 produced a strong positive SARS-CoV-2 signals that resembled those obtained with the kit positive  
147 control (Table S1). Direct testing of highly acidic samples caused invalid results for both Panbio and  
148 Veritor. All other products were Veritor-negative. When nasal swabs were used to sample the various  
149 products and processing occurred with manufacturer buffer, no false positives or invalid results were  
150 observed.

151 Multiple water samples were evaluated with tested pH values between 4.00 and 9.33, and differences in  
152 supplier-described purification methods, and mineral and electrolyte composition (Table 1). Direct  
153 testing onto Panbio test devices showed strong false positive SARS-CoV-2 signals, while samples diluted  
154 in Panbio buffer did not produce any artifacts. Notably, water samples near the pH of the Panbio buffer  
155 (pH 8.78) also displayed strong false positive signals, suggesting the mechanism behind artifact  
156 formation is not, or not solely, pH-dependent. To investigate the possible roles of buffering capacity and  
157 ionic strength, commonly used laboratory buffers and buffer-containing viral transport media spanning

158 various pH values (5.62 to 8.78) were tested (Table 1). With the exception of Tris-EDTA (TE), all other  
159 buffers and media generated weakly positive or negative results (Table 1). All water samples, buffers,  
160 and media were RT-PCR and Veritor-negative, suggesting absence of viral RNA and nucleocapsid antigen,  
161 respectively (Table 1).

162 Given that weak false positive were results observed with UTM, PBS, and saline, direct testing was  
163 performed on clinical specimens containing these media and buffers. With direct testing onto Panbio  
164 cassettes, false positive results were seen in 93.3% of NP swabs in UTM, 86.7% of OP/N swabs in PBS,  
165 90.0% of BALs, and 90.0% of the saline gargles (Table 1). All specimens were negative when Panbio  
166 buffer was used, which was consistent with the Veritor and RT-PCR results.

#### 167 *Role of Panbio buffer components*

168 Tricine solutions at 1M prevented artifact formation at pH values  $\geq 7$ , whereas strong false positive SARS-  
169 CoV-2 results were seen at pH  $\leq 5$  (Figure 1). At 100 mM tricine, buffering capacity was narrowed, and  
170 non-specific SARS-CoV-2 bands were seen at pH  $\leq 8$ . With the exception of invalid results obtained at pH  
171 3 and 12, false positive results at either 1 or 10 mM of tricine when pH ranged between 4 and 11.  
172 Tween-20 (1%) was added to all tricine solutions, but had no impact on results (data not shown). Ionic  
173 strength was assessed with various NaCl concentrations in 100 mM tricine solutions, pH 3 to 12 (Figure  
174 2). High concentration of NaCl (1M) prevented artifact formation, 100 mM reduced it, and lower  
175 concentrations (1 and 10 mM) mirrored NaCl-free conditions (Figure 1 and 2). Antimicrobial agents in  
176 the Panbio buffer (i.e. proclin 300 and sodium azide) were not investigated due to their unlikely  
177 contribution to artifact generation.

#### 178 *Investigations into the mechanism of artifact generation*



179 Following conjugate pad transplantation, positive and negative control swabs displayed expected results  
180 after inoculation onto re-assembled Panbio cassettes in which resuspended conjugated antibodies were  
181 re-introduced. Water-resuspended conjugated antibody generated a strong false positive target signal,  
182 which was eliminated following PK treatment (Figure S2). Removal of the gold-conjugated IgY antibody  
183 from the conjugate suspensions did not impair Panbio test performance, and the strong false positive  
184 SARS-CoV-2 signal from water remained (Figure S2). These findings suggest that the gold-conjugated  
185 human anti-SARS-CoV-2 IgG is responsible for the non-specific interactions with the immobilized anti-  
186 SARS-CoV-2 capture antibody on the test device nitrocellulose membrane. Thermal shift assays in 100  
187 mM tricine solutions were used to compare structural differences of the anti-SARS-CoV-2 IgG at  
188 different pH (Figure S3), and  $T_m$  values were significantly different in tricine solutions between pH 5 to 7  
189 (at  $68.4 \pm 2.6$ ,  $71.4 \pm 1.2$ ,  $72.5 \pm 1.0$ , respectively) compared to pH 8 to 10 (at  $75.6 \pm 1.0$ ,  $76.8 \pm 1.1$  and  
190  $77.6 \pm 1.4$ , respectively) (Figure S3).  $T_m$  values at pH 4 and 11 were inconsistent, while no  $T_m$  values  
191 could be established at pH 3 and 12.

#### 192 *Impact of heat and humidity on Panbio kit function*

193 In all test conditions evaluated (Table S1), no deleterious effects on test sensitivity or specificity were  
194 observed concerning temperature or humidity. In a complimentary series of experiments, Panbio buffer  
195 was able to tolerate dilutions with water (without generating artifacts) up to a ratio of 1:10, regardless  
196 of operating temperature (Figure 3).

#### 197 **Discussion**

198 False positive and negative results occur with any diagnostic test, but are increasingly likely when  
199 manufacturer recommendations are not followed.[1,14,15] Using the Panbio SARS-CoV-2 Ag-RDT, this  
200 study demonstrated test conditions outside manufacturer recommendations that can cause false  
201 positive results. In absence of manufacturer buffer, a variety of food, water, laboratory buffer, specimen

202 transport media, and clinical specimens showed false positive reactions. Uncontrolled conditions of pH,  
203 buffering capacity, and ionic strength, all favored artifact generation, whereas temperature and  
204 humidity were not contributory under the tested parameters.

205 The principal components of the Panbio buffer, tricine and NaCl, were shown to help maintain buffering  
206 capacity, ionic strength, and pH compatible with the proper function of the assay. Panbio buffer diluted  
207 in water at ratios greater than 1:10 resulted in artifact formation. Similarly, when buffering capacity was  
208 poor or lost when using low tricine concentrations (1 or 10 mM), strong false positive signals were seen  
209 across a broad range of pH values. In contrast, high tricine concentrations (100 mM or 1M) prevented  
210 artifact formation at pH 9 and above, which is consistent with the measured pH of Panbio buffer at 8.78.  
211 Similarly, regulated ionic strength also played an important role, as high NaCl concentrations (100 mM  
212 or 1M) reduced or prevented false positive results. Of note, strong artifacts were generated with most  
213 food and water samples, due to their poor buffering capacity and ionic strength, whereas only weak  
214 positive or negative results seen with buffers, media, and clinical specimens. These data are consistent  
215 with others [23] who recognized the importance of Ag-RDT kit buffers.

216 Other possible explanations for false positive Ag-RDT results include cross-reactions [24], interfering  
217 substances [25,26], and improper operating or storage conditions for temperature or humidity.[27].  
218 Cross-reacting or interfering substances common to all samples tested in the study is unlikely.  
219 Temperature extremes have been shown to induce conformational changes in antibodies leading to  
220 non-specific binding [28]; however, in this study, Panbio was unaffected by temperature and humidity.  
221 As mentioned above, the most likely cause of Panbio false positive results was aberrant protein-protein  
222 interactions faced with improper buffer conditions, ionic strength, or pH.

223 In a previous study, 20 of 27 of the malaria Ag-RDTs brands evaluated showed false positive reactions  
224 when the manufacturer buffer was replaced with saline, tap water, or distilled water.[23] Distilled water

225 alone generated false positive reactions [23], similar to what was observed in this study with Panbio.  
226 Possible explanations for their findings included inefficient resuspension of blocking agents, altered  
227 capillary flow rates and decreased flushing of contaminating substances, and finally, non-specific  
228 interactions between the conjugated and capture antibodies faced with uncontrolled buffering and ionic  
229 strength conditions.[23] Tricine is a zwitterionic amino acid with a pKa of 8.26, and in the Panbio buffer,  
230 would be negatively charged at the measured pH of 8.78. Therefore, under recommended testing  
231 conditions, tricine may mask positively charged residues on the SARS-CoV-2-specific conjugated and  
232 capture antibodies, while uncontrolled buffer conditions would favor aberrant electrostatic or  
233 hydrophobic interactions between the two antibodies, resulting in false positive results. Supporting this  
234 theory, PK treatment eliminated the false positive Panbio results generated by water, and the  
235 propensity to generate this artifact varied with buffering capacity, pH, and ionic strength. Removal of  
236 the gold-conjugated chicken IgY (used for control band detection) did not alter formation of the SARS-  
237 CoV-2 target artifact formation, suggesting the SARS-CoV-2-specific conjugated IgG alone is responsible  
238 for non-specific binding and to the SARS-CoV-2-specific capture antibody and artifact formation. Finally,  
239 thermal shift assays were performed on the conjugated anti-SARS-CoV-2 IgG, and pH-dependent  
240 conformation changes were observed under conditions causing false positive results.

241 False positive reactions with the Panbio Ag-RDT have the potential to cause a significant impact to Public  
242 Health. To date, over 200 million Panbio Ag-RDT tests have been distributed to over 120 countries  
243 worldwide, for use in healthcare settings, businesses, or home self-testing. In low prevalence  
244 populations, positive Ag-RDTs are typically confirmed by clinical laboratories with NAATs, thereby  
245 limiting the overall public health impact of the possible artifacts described in this study.[2-4] However, in  
246 programs where home self-testing kits are deployed, it is important to educate users on the importance  
247 of strict adherence to manufacturer instructions. Such education could prevent overuse of public health  
248 and laboratory resources required to investigate false positive reactions, and may alleviate anxieties for

249 the impacted individuals.[17,19,29,30] Another area for consideration is outdoor testing strategies (e.g.  
250 drive-thru testing), where the Panbio kit supplies may be exposed to precipitation and fluctuations in  
251 temperature and humidity.[30] To reduce potential aberrant results from humidity, each Panbio  
252 cassette is packaged with a desiccant; however, hypothetically, once opened, the accumulation of  
253 moisture in humid environments could cause false positive results. Prolonged exposure to elevated  
254 temperatures has been shown to affect the sensitivity of SARS-CoV-2 detection by Ag-RDTs, whereas  
255 low temperatures impaired specificity.[25] This could potentially impact Ag-RDT programs in countries  
256 where extreme environmental conditions are relevant, particularly in those where access to NAAT-  
257 based confirmatory testing is limited. While temperature and humidity did not alter the Panbio  
258 performance in this study, rain water was shown to cause false positive reactions if processed without  
259 buffer. An alternative explanation for the false positives observed at low temperatures by Haage et al  
260 [25] is their use of non-validated specimen types (i.e. NP swabs in PBS). In this study, PBS alone caused  
261 false positive results in absence of buffer, as did most of the saline-based clinical specimens. While PBS  
262 could be a contributing factor in the generation of false positive results, the quantity of PBS material (i.e.  
263 20 µl) used by Haage et al.[25] should not have overwhelmed the kit buffer, as this study demonstrated  
264 tolerance to dilution up to a ratio of 1:10.

265 Overall, this manuscript provides rigorous scientific evidence that erroneous false positive SARS-CoV-2  
266 results can occur with improper test conditions, resulting in non-specific interaction between the SARS-  
267 CoV-2-specific conjugated and capture antibodies. As such, SARS-CoV-2 Ag-RDTs should not deviate  
268 from manufacturer instructions.

## 269 **Acknowledgement**

270 The authors would like to thank the Special Pathogens Program of the National Microbiology Laboratory  
271 (NML) (Winnipeg, MB) for the gamma-irradiated SARS-CoV-2 virus used in this study. We would also like

272 to recognize the ongoing efforts of the all the NML and NSH staff for their dedication and exceptional  
273 services throughout the pandemic, including the help with RT-PCR testing during this evaluation. The  
274 authors would also like to thank all the volunteers and healthcare professionals who dedicate their time  
275 at popup clinics that use Ag-RDTs. You are all instrumental for our pandemic responses, and safety in  
276 our communities.

#### 277 **Author contributions**

278 JH, AB, NS, and JR identified this phenomenon, and were involved in food sample testing. JL, RD, GP, and  
279 TH designed and undertook testing of water, buffer, media, and gargles. JL designed and performed the  
280 buffer reverse engineering, conjugate pad transplanted, PK experiments and DSF experiments. MB,  
281 AM, EM, BH, and PS designed and performed the temperature and humidity experiments. GP, JL, and TH  
282 wrote the initial draft of the manuscript, with all authors contributing to the final version.

#### 283 **Transparency declaration**

284 The authors declare that they have no conflicts of interest. This work received no private or public  
285 funding, with the exception of the Panbio kits that were provided in-kind from the Public Health Agency  
286 of Canada (PHAC).

#### 287 **Ethics**

288 This evaluation was deemed exempt from Nova Scotia Health Research Ethics Board approval, as the  
289 activities described in this manuscript were conducted in fulfillment of ongoing verification of SARS-CoV-  
290 2 diagnostic assays used in Nova Scotia, and are therefore considered a quality assurance initiative.  
291 Clinical specimens tested were obtained from anonymized residual samples collected for routine  
292 diagnostic testing for SARS-CoV-2 from consenting participants, and all data related to clinical specimens  
293 were provided anonymized, de-identified, and were used solely with the intent to evaluate the potential

294 for false positives in these clinical specimen types for rapid antigen testing programs used in Nova  
295 Scotia.

## 296 **References**

- 297 1. Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, Oyewunmi OD, Camargo C, Nikpour B, Armanfard N, Sagan SM,  
298 Jahanshahi-Anbuhi S. 2021. Tools and techniques for severe acute respiratory syndrome coronavirus  
299 2 (SARS-CoV-2)/COVID-19 detection. *Clin Microbiol Rev.* 34(3):e00228-20. doi: 10.1128/CMR.00228-  
300 20. PMID: 33980687.
- 301 2. Public Health Agency of Canada (PHAC). 2020. Interim guidance on the use of rapid antigen  
302 detection tests for the identification of SARS-CoV-2 infection. [https://www.canada.ca/en/public-](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/use-rapid-antigen-detection-tests.html)  
303 [health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/use-rapid-antigen-](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/use-rapid-antigen-detection-tests.html)  
304 [detection-tests.html](https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/use-rapid-antigen-detection-tests.html) (accessed June 21, 2021).
- 305 3. World Health Organization (WHO). 2020. Antigen-detection in the diagnosis of SARS-CoV-2 infection  
306 using rapid immunoassays. Interim guidance. [https://www.who.int/publications/i/item/antigen-](https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2-infection-using-rapid-immunoassays)  
307 [detection-in-the-diagnosis-of-sars-cov-2-infection-using-rapid-immunoassays](https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2-infection-using-rapid-immunoassays) (accessed June 21,  
308 2021)
- 309 4. Centers for Disease Control and Prevention (CDC). 2020. Interim guidance for antigen testing for  
310 SARS-CoV-2. [https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html)  
311 [guidelines.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html) (accessed June 21, 2021).
- 312 5. US Food and Drug Administration. 2020. In vitro diagnostics EUAs. [https://www.fda.gov/medical-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#individual-molecular)  
313 [devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#individual-molecular)  
314 [diagnostics-euas#individual-molecular](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#individual-molecular) (accessed June 21, 2021).

- 315 6. Health Canada. 2020. Authorized medical devices for uses related to COVID-19: List of authorized  
316 testing devices. [https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-  
317 industry/medical-devices/authorized/list.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-<br/>317 industry/medical-devices/authorized/list.html) (accessed June 21, 2021).
- 318 7. Patriquin G, LeBlanc JJ. SARS-CoV-2 sensitivity limbo - How low can we go? *Int J Infect Dis.* 2021  
319 Feb;103:23-24. doi: 10.1016/j.ijid.2020.11.138. Epub 2020 Nov 17. PMID: 33212261; PMCID:  
320 PMC7669480.
- 321 8. Merino P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán JC, Antona N, Cilla G, Hernández-  
322 Crespo S, Díaz-de Tuesta JL, Gual-de Torrella A, González-Romo F, Escribano P, Sánchez-Castellano  
323 MÁ, Sota-Busselo M, Delgado-Iribarren A, García J, Cantón R, Muñoz P, Folgueira MD, Cuenca-  
324 Estrella M, Oteo-Iglesias J; Spanish Panbio™ COVID-19 validation group. 2021. Multicenter  
325 evaluation of the Panbio COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2  
326 infection. *Clin Microbiol Infect.* 27(5):758-61. doi: 10.1016/j.cmi.2021.02.001. Epub ahead of print.  
327 PMID: 33601009; PMCID: PMC7884234.
- 328 9. Scheiblaue H, Filomena A, Nitsche A, Puyskens A, Corman VM, Drosten C, Zwirgmaier K, Lange C,  
329 Emmerich P, Müller M, Knauer O, Nübling CM. 2021. Comparative sensitivity evaluation for 122  
330 CE-marked SARS-CoV-2 antigen rapid tests. medRxiv 2021.05.11.21257016; doi:  
331 <https://doi.org/10.1101/2021.05.11.21257016>
- 332 10. Gremmels H, Winkel BMF, Schuurman R, Rosingh A, Rigter NAM, Rodriguez O, Ubijaan J, Wensing  
333 AMJ, Bonten MJM, Hofstra LM. 2021. Real-life validation of the Panbio COVID-19 antigen rapid test  
334 (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection.  
335 *EClinicalMedicine* 31:100677. <https://doi.org/10.1016/j.eclinm.2020.100677>.
- 336 11. Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F, Gómez-Herruz P, Arroyo T,  
337 Cuadros J. 2020. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7

- 338 days after the onset of symptoms. *J Clin Virol*. 133:104659. doi: 10.1016/j.jcv.2020.104659. Epub  
339 2020 Oct 16. PMID: 33160179; PMCID: PMC7561603.
- 340 12. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, Martínez M, Poujois S,  
341 Forqué L, Valdivia A, Solano de la Asunción C, Ferrer J, Colomina J, Navarro D. 2021. Field evaluation  
342 of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary  
343 healthcare centres. *Clin Microbiol Infect*. 27(3):472.e7-472.e10. doi: 10.1016/j.cmi.2020.11.004.  
344 Epub 2020 Nov 13. PMID: 33189872; PMCID: PMC7662075.
- 345 13. Stokes W, Berenger BM, Portnoy D, Scott B, Szelewicki J, Singh T, Venner AA, Turnbull L, Pabbaraju  
346 K, Shokoples S, Wong AA, Gill K, Guttridge T, Proctor D, Hu J, Tipples G. 2021. Clinical performance of  
347 the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals  
348 with COVID-19. *Eur J Clin Microbiol Infect Dis*. 20:1-6. doi: 10.1007/s10096-021-04202-9. Epub  
349 ahead of print. PMID: 33742322; PMCID: PMC7979467.
- 350 14. Food and Drug Administration (FDA). 2020. Potential for false positive results with antigen tests for  
351 rapid detection of SARS-CoV-2 - Letter to clinical laboratory staff and health care providers.  
352 [https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-positive-results-](https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-positive-results-antigen-tests-rapid-detection-sars-cov-2-letter-clinical-laboratory)  
353 [antigen-tests-rapid-detection-sars-cov-2-letter-clinical-laboratory](https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-positive-results-antigen-tests-rapid-detection-sars-cov-2-letter-clinical-laboratory) (accessed June 21, 2021).
- 354 15. Nikolayevskyy V, Drobniewski F. 2020. False-positive COVID-19 results: hidden problems and costs.  
355 *Lancet Respir Med*. 8(12):1167-1168. doi: 10.1016/S2213-2600(20)30453-7. Epub 2020 Sep 29.  
356 PMID: 33007240; PMCID: PMC7524437.
- 357 16. LeBlanc JJ, Heinsteinst C, MacDonald J, Pettipas J, Hatchette TF, Patriquin G. 2020. A combined  
358 oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of  
359 SARS-CoV-2. *J Clin Virol*. 128:104442. doi: 10.1016/j.jcv.2020.104442. Epub 2020 May 16. PMID:  
360 32540034; PMCID: PMC7228872.



- 361 17. Patriquin G, Davis I, Heinstein C, MacDonald J, Hatchette TF, LeBlanc JJ. 2020. Exploring alternative  
362 swabs for use in SARS-CoV-2 detection from the oropharynx and anterior nares. *J Virol Methods*.  
363 285:113948. doi: 10.1016/j.jviromet.2020.113948. Epub 2020 Aug 9. PMID: 32783913; PMCID:  
364 PMC7415171.
- 365 18. Goldfarb DM, Tilley P, Al-Rawahi GN, Srigley JA, Ford G, Pedersen H, Pabbi A, Hannam-Clark S,  
366 Charles M, Dittrick M, Gadkar VJ, Pernica JM, Hoang LMN. 2021. Self-collected saline gargle samples  
367 as an alternative to health care worker-collected nasopharyngeal swabs for COVID-19 diagnosis in  
368 outpatients. *J Clin Microbiol*. 59(4):e02427-20. doi: 10.1128/JCM.02427-20. PMID: 33514627.
- 369 19. LeBlanc JJ, Pettipas J, Di Quinzio M, Hatchette TF, Patriquin G. 2021. Reliable detection of SARS-CoV-  
370 2 with patient-collected swabs and saline gargles: A three-headed comparison on multiple molecular  
371 platforms. *Journal of Virological Methods* 295:114184. doi: 10.1016/j.jviromet.2021.114184. Epub  
372 ahead of print. PMID: 34029634; PMCID: PMC8141269.
- 373 20. Davey L, Cohen A, LeBlanc J, Halperin SA, Lee SF. 2016. The disulfide oxidoreductase SdbA is active in  
374 *Streptococcus gordonii* using a single C-terminal cysteine of the CXXC motif. *Mol Microbiol*.  
375 99(2):236-53. doi: 10.1111/mmi.13227. Epub 2015 Oct 30. PMID: 26395460.
- 376 21. Gao K, Oerlemans R, Groves MR. 2020. Theory and applications of differential scanning fluorimetry  
377 in early-stage drug discovery. *Biophys Rev*. 12(1):85-104. doi: 10.1007/s12551-020-00619-2. Epub  
378 2020 Jan 31. PMID: 32006251; PMCID: PMC7040159.
- 379 22. Ramu T, Prasad ME, Connors E, Mishra A, Thomassin JL, LeBlanc JJ, Rainey JK, Thomas NA. 2013. A  
380 novel C-terminal region within the multicargo type III secretion chaperone CesT contributes to  
381 effector secretion. *J Bacteriol*. 195(4):740-56. doi: 10.1128/JB.01967-12. Epub 2012 Dec 7. PMID:  
382 23222727; PMCID: PMC3562101.

- 383 23. Gillet P, Mori M, Van den Ende J, Jacobs J. 2010. Buffer substitution in malaria rapid diagnostic tests  
384 causes false-positive results. *Malar J.* 9:215. doi: 10.1186/1475-2875-9-215. PMID: 20650003;  
385 PMCID: PMC3224932.
- 386 24. Wanji S, Amvongo-Adjia N, Njouendou AJ, Kengne-Ouafo JA, Ndongmo WP, Fombad FF, Koudou B,  
387 Enyong PA, Bockarie M. 2016. Further evidence of the cross-reactivity of the Binax NOW Filariasis  
388 ICT cards to non-*Wuchereria bancrofti* filariae: experimental studies with *Loa loa* and *Onchocerca*  
389 *ochengi*. *Parasit Vectors.* 9:267. doi: 10.1186/s13071-016-1556-8. PMID: 27151313; PMCID:  
390 PMC4858834.
- 391 25. Selby C. 1999. Interference in immunoassay. *Ann Clin Biochem.* 36(6):704-21. doi:  
392 10.1177/000456329903600603. PMID: 10586307.
- 393 26. Nivin B, Zancocchio T. 2012. Cluster of false-positive influenza B virus rapid antigen test results in a  
394 New York City hospital. *J Clin Microbiol.* 50(9):3141. doi: 10.1128/JCM.01452-12. Epub 2012 Jun 20.  
395 PMID: 22718940; PMCID: PMC3421782.
- 396 27. Haage V, Ferreira de Oliveira-Filho E, Moreira-Soto A, Kühne A, Fischer C, Sacks JA, Corman VM,  
397 Müller MA, Drosten C, Drexler JF. 2021. Impaired performance of SARS-CoV-2 antigen-detecting  
398 rapid diagnostic tests at elevated and low temperatures. *J Clin Virol.* 138:104796. doi:  
399 10.1016/j.jcv.2021.104796. Epub 2021 Mar 16. PMID: 33773413; PMCID: PMC7962993.
- 400 28. Lin J, Dai W, Li W, Xiao L, Luo T, Guo Y, Yang Y, Han Y, Zhu P, Wu Q, He B, Wu J, Xia X. 2021. Potential  
401 false-positive and false-negative results for COVID-19 IgG/IgM antibody testing after heat-  
402 inactivation. *Front Med (Lausanne).* 7:589080. doi: 10.3389/fmed.2020.589080. PMID: 33537325;  
403 PMCID: PMC7849051.
- 404 29. Wehrhahn MC, Robson J, Brown S, Bursle E, Byrne S, New D, Chong S, Newcombe JP, Siversten T,  
405 Hadlow N. 2020. Self-collection: An appropriate alternative during the SARS-CoV-2 pandemic. *J Clin*

406 Virol. 128:104417. doi: 10.1016/j.jcv.2020.104417. Epub 2020 May 4. PMID: 32403007; PMCID:  
407 PMC7198188.

408 30. Siegler AJ, Hall E, Luisi N, Zlotorzynska M, Wilde G, Sanchez T, Bradley H, Sullivan PS. 2020.  
409 Willingness to seek diagnostic testing for SARS-CoV-2 with home, drive-through, and clinic-based  
410 specimen collection locations. Open Forum Infect Dis. 7(7):ofaa269. doi: 10.1093/ofid/ofaa269.  
411 PMID: 32704517; PMCID: PMC7337815.

412

413

414

415

#### 416 **Figure legends**

417 **Figure 1.** False positives SARS-CoV-2 Ag-RDT results can occur from uncontrolled pH and buffering  
418 conditions. All tricine solutions were prepared in PCR-grade water known to generate false positive  
419 signals when tested directly onto Panbio test devices.

420 **Figure 2.** Impact of ionic strength from NaCl on the presence of false positive SARS-CoV-2 signal  
421 generated by direct processing of PCR-grade water.

422 **Figure 3.** Tolerability of the Panbio buffer to artifact generation by PCR-grade water at different  
423 temperatures.

424 **Figure S1.** Conjugate pad transplanted to access and investigate properties of the proprietary Panbio  
425 conjugated antibodies. Each step was followed to as depicted leading to treatment of the conjugated  
426 antibodies with proteinase K (PK) or heat (T°C), and comparisons were made with untreated controls

427 (none). In some experiments (dashed arrows), the gold-conjugated antibody suspensions were pre-  
 428 treated with the control antibody (mouse anti-chicken IgY) was used to purify the SARS-CoV-2-specific  
 429 conjugated antibody (human IgG) for subsequent thermal shift assays.

430 **Figure S2.** Proteinase K treatment of the conjugated antibodies and removal of chicken IgY. A)  
 431 Proteinase K (PK) treatment. Using conjugate pad transplantation, gold-conjugated antibody  
 432 suspensions in Panbio buffer or water were treated for an hour with PK at 56°C, followed by heat  
 433 inactivation of PK at 70°C for 10 min. Following re-introduction into Panbio cassettes of conjugated  
 434 antibodies that were untreated (none), heat-treated (T°C), or PK-treated, water and a negative control  
 435 swab, and with buffer with either a positive or negative control swab were added to the sample well. B)  
 436 To purify the SARS-CoV-2-specific conjugated antibody (human IgG) from the conjugated antibody  
 437 suspensions, a pre-incubation with the control antibody (mouse anti-chicken IgY) excised from the  
 438 nitrocellulose membrane was performed. Untreated (none) or pre-treatment (-IgY) are depicted for  
 439 reassembled Panbio cassettes inoculated with negative or positive control swabs processed in buffer or  
 440 water.

441 **Figure S3.** Representative thermal shift profiles for Panbio SARS-CoV-2-specific conjugated antibody at  
 442 different pH values in 100 mM tricine. Melt temperatures (T<sub>m</sub>) are indicated for each curve.

443

444 **Table 1.** Samples tested by SARS-CoV-2 Ag-RDTs with and without manufacturer buffer.

Category	Brand	Description	Avg. pH (± SD)	Panbio result		Veritor result		RT-PCR result
				Sample, direct	Swab of sample in buffer	Sample, direct	Swab of sample in buffer	
Water samples	Sigma Life Sciences	Double processed,	4.00 (± 0.01)	POS	NEG	NEG	NEG	NEG

(n=24)		tissue culture water, sterile filtered						
	Montellier	Carbonated spring water	4.68 (± 0.00)	POS	NEG	NEG	NEG	NEG
	Invitrogen	UltraPure distilled water, Dnase- and Rnase-free	4.80 (± 0.01)	POS	NEG	NEG	NEG	NEG
	Aquafina	Demineralized water, reverse osmosis	5.05 (± 0.01)	POS	NEG	NEG	NEG	NEG
	S. Pellegrino	Carbonated natural mineral water	5.09 (± 0.01)	POS	NEG	NEG	NEG	NEG
	Canadian Springs	Distilled water, ozonized	5.31 (± 0.01)	POS	NEG	NEG	NEG	NEG
	Dasani	Remineralized water, reverse osmosis treated	5.68 (± 0.01)	POS	NEG	NEG	NEG	NEG
	Big8	Distilled water, ozonated	6.25 (± 0.01)	POS	NEG	NEG	NEG	NEG
	Big8	Spring water, ozonated	6.26 (± 0.01)	POS	NEG	NEG	NEG	NEG
	Glaceau Smart	Vapour distilled water with added electrolytes	6.71 (± 0.02)	POS	NEG	NEG	NEG	NEG
	N/A	Municipal water (Halifax, Nova Scotia, May12, 2021)	6.75 (± 0.02)	POS	NEG	NEG	NEG	NEG
	Fiji	Natural spring water, tropical rain filtered through volcanic rock	7.25 (± 0.02)	POS	NEG	NEG	NEG	NEG
	Simple Drop	Natural spring water	7.26 (± 0.02)	POS	NEG	NEG	NEG	NEG
	Pathwater	Purified water, reverse osmosis treated,	7.27 (± 0.01)	POS	NEG	NEG	NEG	NEG

		ozonated, and electrolytes added, pH-balanced, pH 7.5+						
	Art Life WTR	Purified water, mineralized and electrolytes added, pH-balanced	7.28 (± 0.01)	POS	NEG	NEG	NEG	NEG
	Evian	Spring water, natural electrolytes, pH 7.2	7.39 (± 0.02)	POS	NEG	NEG	NEG	NEG
	N/A	Rain water (Halifax, Nova Scotia, May 12, 2021)	7.47 (± 0.01)	POS	NEG	NEG	NEG	NEG
	Icelandic Glacial	Natural spring water	7.58 (± 0.02)	POS	NEG	NEG	NEG	NEG
	Nestle Pure Life	Natural spring water, ozonated	7.75 (± 0.02)	POS	NEG	NEG	NEG	NEG
	Earth Group	Spring water	7.80 (± 0.03)	POS	NEG	NEG	NEG	NEG
	Eska	Natural spring water, pH 7.4	7.81 (± 0.00)	POS	NEG	NEG	NEG	NEG
	#Smart Moodwater	Naturally alkaline spring water, pH 8+	7.91 (± 0.01)	POS	NEG	NEG	NEG	NEG
	Flow	Naturally alkaline spring water, pH 8.1	8.02 (± 0.00)	POS	NEG	NEG	NEG	NEG
	Glaceau Smart	Mineralized treated water, alkaline pH 9+	9.33 (± 0.00)	POS	NEG	NEG	NEG	NEG
Laboratory buffers and media (n=14)	Teligent	0.9% Saline	5.62 (± 0.02)	POS (weak)	NEG	NEG	NEG	NEG
	Boston BioProducts	0.5M Pipes buffer, pH 6.8	6.66 (± 0.01)	POS*	NEG	NEG	NEG	NEG
	FisherScientific	10 mM Tris-HCl; 1 mM EDTA (TE) buffer, molecular-	7.14 (± 0.01)	POS	NEG	NEG	NEG	NEG

		grade pH 7.4						
	Sigma Life Sciences	Dulbecco's Phosphate Buffered Saline (PBS)	7.18 (± 0.01)	POS*	NEG	NEG	NEG	NEG
	LiofilChem	Viral Transport Media (VTM)	7.24 (± 0.01)	POS*	NEG	NEG	NEG	NEG
	Redoxica	Viral Transport Media (VTM) with fetal bovine serum (FBS)	7.33 (± 0.01)	POS*	NEG	NEG	NEG	NEG
	Becton Dickinson	Veritor sample buffer	7.33 (± 0.00)	NEG	NEG	NEG	NEG	NEG
	Copan Diagnostics	Universal Transport Medium (UTM)	7.37 (± 0.01)	NEG	NEG	NEG	NEG	NEG
	Yokon	Universal Transport Medium (UTM)	7.44 (± 0.01)	NEG	NEG	NEG	NEG	NEG
	Gibco	RPMI medium 1640, with HEPES	7.48 (± 0.01)	NEG	NEG	NEG	NEG	NEG
	Genesis	KaiBiLi Extended ViralTrans, includes HEPES	7.50 (± 0.01)	NEG	NEG	NEG	NEG	NEG
	Gibco	Minimal Essential Media (MEM)	7.83 (± 0.01)	NEG	NEG	NEG	NEG	NEG
	Gibco	1x Phosphate Buffered Saline (PBS), pH 7.4	8.20 (± 0.01)	NEG	NEG	NEG	NEG	NEG
	Abbott	Panbio sample buffer	8.78 (± 0.01)	NEG	NEG	NEG	NEG	NEG
Clinical specimens (n=120)	N/A	NP swabs in UTM (n=30)	N/A	POS* (28/30)	NEG	NEG	NEG	NEG
	N/A	OP/N swabs in PBS (n=30)	N/A	POS* (26/30)	NEG	NEG	NEG	NEG
	N/A	BALs (n=30)	N/A	POS* (27/30)	NEG	NEG	NEG	NEG

	N/A	Saline gargles (n=30)	N/A	POS* (27/30)	NEG	NEG	NEG	NEG
--	-----	--------------------------	-----	-----------------	-----	-----	-----	-----

445 \*Only weak positive reactions were observed.


446

447

448




Tricine





# Panbio buffer:water



Temperature

